Novo Nordisk will reduce the US list price of some of its insulin products by up to 75%, the Danish drugmaker saying Tuesday.
The change, which will take effect on January 1, 2024, follows a similar move by Eli Lilly, which said this month it will cut the list price of several of its products, including Humalog, by 70% by the end of this year. .
But Eli Lilly also went one step further, immediately limiting the out-of-pocket cost of all its insulin products to $35 per month.
President Joe Biden praised Eli Lilly at the time and called on other insulin makers to do the same.
Eli Lilly and Novo Nordisk, along with French pharmaceutical company Sanofi, make up more than 90% of the insulin market in the U.S.
Following Eli Lilly’s announcement, experts predicted that other insulin makers would make changes as well.
“Novo Nordisk is playing follow-the-leader here after Eli Lilly cut prices on insulin products substantially,” said Larry Levitt, executive vice president of health policy at KFF, formerly known as the Kaiser Family Foundation.
Stacie Dusetzina, a professor of health policy at Vanderbilt University Medical Center in Nashville, Tennessee, said the company also faces stiff competition for these drugs.
“They have little to lose by making this change,” he said.
Novo Nordisk said Tuesday that its popular NovoLog and NovoLog Mix 70/30 rapid-acting insulins will cost $72.34 for a single vial and $139.71 for a pen, a 75% price drop.
The price of Levemir, a long-acting insulin, will be cut by 65% to $107.85 per vial and $161.77 per pen, the company said. Novolin will see a similar price reduction, to $48.20 per vial and $91.09 per pen.
Most consumers don’t end up paying full list price for a drug; the out-of-pocket cost they pay at the pharmacy will depend on their insurance. Seniors with Medicare won’t pay more than $35 a month out-of-pocket, thanks to a provision of the Cut Inflation Act that went into effect January 1.
Levitt said the Novo Nordisk measure will likely provide the most relief for those who are uninsured or have high deductibles.
Novo Nordisk will continue to offer programs to make insulin more affordable.
“Novo Nordisk remains committed to ensuring that patients living with diabetes can afford our insulins, a responsibility we take seriously,” Steve Albers, the company’s senior vice president of market access and public affairs, said in a statement.
Insulin costs in the US are higher compared to other countries. According to the Rand Corporation, a public policy think tank, in 2018, the average list price for a vial of insulin in the US was $98.70.

